Navigation Links
BioLineRx Presents Data From Successful Phase I Trial for BL-1020,in Schizophrenia at American Psychiatric Association Conference

m the Department of Chemistry, Bar-Ilan University; and Ada Rephaeli, Ph.D., Professor Abraham Weizman, MD, and Irit Gil-Ad, Ph.D. from the Sackler Faculty of Medicine, Tel Aviv University.

About BioLineRx

BioLineRx, a clinical stage drug development company traded on the Tel Aviv Stock Exchange (TASE:BLRX), is dedicated to building a robust pipeline of promising therapeutics for unmet medical needs. The Company's leading programs are for schizophrenia and treatment of damaged heart tissue post-myocardial infarction. Additional products under development include compounds for the treatment of cancer and CNS, cardiovascular, metabolic, infectious and autoimmune diseases.

BioLineRx advances projects from early stage discovery and lead generation to advanced clinical trials, regulatory approval and marketing. Partnering with researchers, universities and biotech companies to further the commercialization of promising compounds, BioLineRx seeks to enrich the pipeline of large pharmaceutical companies seeking their next blockbuster drugs. The Company was founded in 2003 by leaders in the Israeli life science arena including Teva Pharmaceuticals Ltd, Giza, Pitango, Hadasit and the Jerusalem Development Authority. For more information, please visit www.biolinerx.com.

This press release contains "forward-looking statements." These statements include words like "may," "expects," "believes," "scheduled" and "intends," and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

Contact

BioLineRx Ltd.
Yuri Shoshan, +972-2-548-9100
VP Finance and Corporate Development
yuri@biolinerx.com
'"/>




Page: 1 2 3 4

Related medicine technology :

1. BioLineRx Presents Phase I Clinical Data of BL-1020 at Upcoming Clinical Conferences
2. BioLineRx Presents Data on BL-1040 at Cardiovascular Revascularization Therapies Conference Demonstrating Potential to Reduce Deterioration of Infarcted Heart Tissue and Maintain Functionality
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
5. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
6. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
7. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
8. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
9. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
10. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
11. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
Post Your Comments:
(Date:8/26/2008)...RT WORTH, Texas, Aug. 26 /- Healthpoi...l trial to evaluate the effectiveness of a,widely ...taneous wounds and,resulting scars. The pilot stud...e reduced incidence of hypertrophic scars and bene...ase SANTYL(R) Ointment.(1,2), "Given the findings...
(Date:8/25/2008)... Discovers Stem Cells Found in Menstrual Blood May...cts for Time-Pressed Women, OLDSMAR, Fla., Aug. 2.... Yet most women would agree that there never seem... a woman spends on doing something just,for hersel...sts in others.,This reality has led many women in ...
(Date:8/25/2008)...t Line CLL, NHL and CLL Retreatment and Japanese D...Planned, COPENHAGEN, Denmark, August 25 /PRNewswi...in four studies of ofatumumab in chronic lymphocyt.../S (OMX: GEN) announced today plans to begin four ...mia (CLL) and follicular,non-Hodgkin,s lymphoma (N...
(Date:8/21/2008)...NHATTAN, Kan., Aug. 21 /PRNewswire-USNewswire/ -- ...E. coli O157:H7 expert T.G. Nagaraja has,been tapp...both the,connection between feeding distillers, gr...ategies to reduce the presence of the naturally oc...eceived a $939,220 National Research Initiative in...
Breaking Medicine Technology:Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing 2Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing 3Going Beyond 'Spa Day': Giving Women the Opportunity to Do Something Proactive Which May Lead to Long Term Health Benefits 2Genmab Announces Upcoming Ofatumumab Studies 2Genmab Announces Upcoming Ofatumumab Studies 3Genmab Announces Upcoming Ofatumumab Studies 4K-State Researchers Awarded Nearly $1 Million to Test Remedies, Investigate Link Between E. Coli and Distillers' Grains 2Dr Amit Dhawan Promoted to Medical Director for The Mattson Jack Group 114 1Dr Amit Dhawan Promoted to Medical Director for The Mattson Jack Group 114 2Dr Amit Dhawan Promoted to Medical Director for The Mattson Jack Group 114 3UK junior doctors gaining less experience of common procedures 115 1UK junior doctors gaining less experience of common procedures 115 2Ancient organisms discovered in Canadian gold mine 110 1Ancient organisms discovered in Canadian gold mine 110 2Survey reveals disparities in skin cancer knowledge protection among high school students 110 1Survey reveals disparities in skin cancer knowledge protection among high school students 110 2Survey reveals disparities in skin cancer knowledge protection among high school students 110 3
...a,clinical stage nanomedicine company focused on t...ional, tumor-targeted therapies has,been selected ...Society of Clinical Oncology Annual Meeting in Chi...ake place from 8:00 am to 12,noon on June 3. Dr. L...e poster abstract entitled "Preliminary Results of...
...from a large,randomized clinical trial for patien... typically found in bone marrow, has,shown that th...Decadron ®), in combination with lenalidomide ...val when compared to a treatment,regimen with lena...one. The clinical trial was sponsored by the Natio...
Other Medicine Technology:CytImmune To Present At ASCO Phase I Clinical Trial of CYT-6091 to,be Presented on June 3, 2007 2Low-Dose Steroid Combined With Lenalidomide Prolongs Survival,Compared With High-Dose Steroid for Multiple Myeloma Treatment 2Low-Dose Steroid Combined With Lenalidomide Prolongs Survival,Compared With High-Dose Steroid for Multiple Myeloma Treatment 3
(Date:8/29/2008)...esults of a 10-year study published in the August ...found that magnesium sulfate administered to women...he risk of cerebral palsy by 50 percent. The Benef...) trial was conducted in 18 centers in the U.S., i...renatal intervention ever found to reduce the inst...
(Date:8/29/2008)... http://www.aronowitzmd.com [Los An...espected experience in plastic surgery procedures ...consideration may be necessary for these patients,...e an established specialty of procedures for after...es, CA (PRWEB) August 29, 2008 -- Bariatric surger...
(Date:8/28/2008)...ues increase 138% versus Q2 2007 - Nine new Cen...RNewswire-FirstCall/ - CRH Medical Corporation,(CR... three and six months,ended June 30, 2008 (all fig...ths ended June 30, 2008 increased 138% to $1,653,8...7. Revenue for the six months ended June,30, 2008 ...
(Date:8/28/2008)...ion will be based in the Northeast region with mor...xt year, HARRISBURG, Pa., Aug. 28 /PRNewswire-USN...ity has hired a Patient Safety Liaison for the,Nor...eport to the,Pennsylvania Patient Safety Reporting...ylvania citizens., "Last year in focus groups wit...
Breaking Medicine News(10 mins):Health News:National study shows magensium sulfate reduces risk of cerebral palsy in premature births 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 3Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 4Health News:CRH Medical reports Q2 2008 results 2Health News:CRH Medical reports Q2 2008 results 3Health News:CRH Medical reports Q2 2008 results 4Health News:CRH Medical reports Q2 2008 results 5Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 2Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 3
...common and deadly cancer worldwide. About 1.4 mill...out of which // 85% will die before 2010. Habit of... it is fastly increasing in low and middle income ...r occurrence is smoking. Globally smoking related ...
... or more pounds above ideal body weight. Obesity i...in developed countries. According to a recent rep...ently about 31 percent. In 1980 it was 23% and 15 ...ses problems with heart but also many other diseas...
...udy researchers say the drug orlistat (Xenical) co...ithout // major side effects in overweight teens. ...estines to absorb fat by up to 30 percent. However...istat passes through the body without being digest...
...to the fact that uncomplicated twin pregnancies ma...e. Researchers of Imperial College London report t...es have an increased risk from intrauterine deaths...egnancy, the twin fetuses share the same placenta ...
Other Medicine News:Health News:Aggressive Tobacco taxation policy can reduce cigarette smoking, 2
4 mm wide tip.
Double-ended. 3 mm x 5 mm curette end and 3 mm spatula end.
2.5 mm x 4 mm opening. Hexagonal handle.
Double-ended. Sharp and blunt 6.5 mm tips. Designated most popular model or size.
Medicine Products: